首页> 美国卫生研究院文献>Endocrinology Diabetes Metabolism Case Reports >Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour

【2h】

Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour

机译：恶性多分泌胰腺神经内分泌肿瘤患者中奥曲肽LAR剂量升高后延长危及生命的低血糖

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Endocrinology Diabetes Metabolism Case Reports
作者
Sally K Abell; Jessie Teng; Anthony Dowling; Michael S Hofman; Richard J MacIsaac; Nirupa Sachithanandan;
展开▼
作者单位

展开▼
年(卷),期 2015(2015),-1
年度 2015
页码 140097
总页数 5
原文格式 PDF
正文语种
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour [J] . Sally K Abell, Jessie Teng, Anthony Dowling, Endocrinology, Diabetes & Metabolism Case Reports . 2015,第1期

机译：恶性多分泌胰腺神经内分泌肿瘤患者中奥曲肽LAR剂量升高后延长危及生命的低血糖
2. Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression. [J] . Verslype C Acta gastro-enterologica Belgica . 2011,第1期

机译：对于晚期胃肠道神经内分泌肿瘤患者，奥曲肽LAR的剂量递增是安全有效的，可控制症状和肿瘤进展。
3. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. [J] . Woltering EA, Mamikunian PM, Zietz S, Pancreas . 2005,第4期

机译：奥曲肽LAR剂量和重量对神经内分泌肿瘤患者奥曲肽血药浓度的影响。
4. Determination of Dose Escalation Region in Malignant Brain tumors for Radiation Treatment Planning Based on Apparent Diffusion Coefficient Map [C] . J.Y Park, KJ Ahn, D.C Woo, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：基于表观扩散系数图确定恶性脑肿瘤剂量递增区域以进行放射治疗计划
5. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification [D] . Takahashi Daigoro, 高橋大五郎 2019

机译：用多光谱成像分析胰腺神经内分泌肿瘤的肿瘤免疫微环境表明符合WHO 2017分类的不同亚群特征
6. Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study [O] . Jonathan R. Strosberg, Al B. Benson, Lynn Huynh, 2014

机译：多剂量奥曲肽LAR在神经内分泌肿瘤患者中控制类癌综合征症状的临床益处：多中心回顾性图表审查研究
7. Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly [O] . Annamaria Colao, Rosario Pivonello, Renata S Auriemma, 2007

机译：剂量升级的辛酸剂量升级为一肢疗效

Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour

著录项

相似文献

相关主题

期刊订阅